Meeting
2023 ASCO Annual Meeting
Homologous recombination deficiency (HRD) in non-small cell lung cancer: Genomic analysis using an RNA-based HRD algorithm.
Authors
Stephanie Thiede
Tempus Labs, Inc., Chicago, IL
Stephanie Thiede , Matthew Berginski , Akash Mitra , Timothy J. Taxter , Michelle M. Stein , Rotem Ben-Shachar , Halla Nimeiri , Charu Aggarwal , Jyoti D. Patel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3123)
DOI
10.1200/JCO.2023.41.16_suppl.3123
Abstract #
3123
Poster Bd #
321
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real life use of biomarkers of homologous recombination deficiency (HRD) status beyond BRCA to predict the effectiveness of PARP inhibitors in ovarian cancer patients.
First Author: Lorena Incorvaia
Poster
2023 ASCO Annual Meeting
Exploring the significance of PARP inhibitor therapy after first-line chemotherapy in patients with homologous recombination proficient ovarian cancer: An extracted individual patient data and trial-level meta-analysis.
First Author: Mateus Trinconi Cunha
Poster
2023 ASCO Annual Meeting
Systematic high-throughput combination drug screen to enhance poly (ADP-ribose) polymerase (PARP) inhibitor efficacy in ovarian cancer.
First Author: Katherine Foster
Poster
2023 ASCO Annual Meeting
Final results of a pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the homologous recombination DNA repair pathway.
First Author: Ruben Raychaudhuri